Real-world immuno-oncology treatment patterns and outcomes in US patients with metastatic non-small-cell lung cancer.

e20537Background: Three immune-oncology (IO) agents are approved by the FDA to treat metastatic NCSLC (mNSCLC). This retrospective observational study aimed to observe treatment patterns and real-w...